HealthEquity, Inc. (NASDAQ:HQY – Get Free Report) CEO Jon Kessler sold 32,326 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $82.83, for a total value of $2,677,562.58. Following the sale, the chief executive officer now owns 232,176 shares of the company’s stock, valued at $19,231,138.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
HealthEquity Stock Performance
Shares of HQY opened at $86.20 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 4.39 and a current ratio of 4.39. The stock has a 50-day moving average of $81.03 and a two-hundred day moving average of $78.04. The stock has a market cap of $7.50 billion, a P/E ratio of 93.70, a P/E/G ratio of 1.40 and a beta of 0.55. HealthEquity, Inc. has a one year low of $61.32 and a one year high of $87.72.
HealthEquity (NASDAQ:HQY – Get Free Report) last released its earnings results on Monday, June 3rd. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.08. HealthEquity had a return on equity of 7.77% and a net margin of 7.71%. The firm had revenue of $287.60 million during the quarter, compared to the consensus estimate of $278.78 million. As a group, research analysts predict that HealthEquity, Inc. will post 2.12 EPS for the current year.
Institutional Trading of HealthEquity
Analyst Ratings Changes
A number of equities analysts have commented on HQY shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a report on Tuesday, June 4th. JMP Securities increased their target price on shares of HealthEquity from $101.00 to $105.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 4th. JPMorgan Chase & Co. lifted their price target on shares of HealthEquity from $86.00 to $108.00 and gave the stock an “overweight” rating in a report on Tuesday, April 2nd. Robert W. Baird increased their price objective on HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a report on Tuesday, June 4th. Finally, BTIG Research boosted their target price on HealthEquity from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.67.
Read Our Latest Report on HealthEquity
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
See Also
- Five stocks we like better than HealthEquity
- High Flyers: 3 Natural Gas Stocks for March 2022
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Investing In Automotive Stocks
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Profitably Trade Stocks at 52-Week Highs
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.